Vera Therapeutics, Inc. (NASDAQ: VERA) is emerging as one of the most promising small-cap stocks with significant upside potential.
On October 16, Bank of America (BofA) initiated coverage of Vera Therapeutics with a Buy rating and set a price target of $48.
The firm highlighted the potential growth in Vera’s shares, largely driven by its lead drug, atacicept, which has shown encouraging prospects in its development pipeline.
Investors are paying close attention to these developments as Vera Therapeutics continues to advance its clinical programs and aims to capitalize on its innovative treatments.
https://www.insidermonkey.com/blog/bofa-initiates-coverage-of-vera-therapeutics-vera-with-a-buy-rating-1630305/